Cargando…
Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome that affects multiple organ systems. We present the case of a 47-year-old African American male with a two-year history of a slowly enlarging right lower back lesion. Upo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489551/ https://www.ncbi.nlm.nih.gov/pubmed/34650853 http://dx.doi.org/10.7759/cureus.17675 |
_version_ | 1784578362217332736 |
---|---|
author | Eubanks, Bianca N Tafti, Dawood A House, Sabrina Logemann, Nicholas |
author_facet | Eubanks, Bianca N Tafti, Dawood A House, Sabrina Logemann, Nicholas |
author_sort | Eubanks, Bianca N |
collection | PubMed |
description | Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome that affects multiple organ systems. We present the case of a 47-year-old African American male with a two-year history of a slowly enlarging right lower back lesion. Upon workup, the 3 × 2 cm mass was biopsied confirming a diagnosis of DFSP. This was identified in concert with axillary freckling, café-au-lait spots, and pedunculated plaques evaluated with biopsy. The findings were consistent with neurofibromas, leading to a new diagnosis of NF1. The patient was definitively treated with wide local excision of the DFSP lesion without tumor recurrence over six years. DFSP has a favorable prognosis when treated with wide local excision and negative surgical margins. However, lesions may recur with inadequate margins. Although deferred in our patient, treatment with imatinib mesylate, a tyrosine kinase inhibitor, may be employed in the setting of advanced disease, metastasis, positive surgical margins, or irresectable locations. Imatinib has also been used to treat NF1. Hence, we posit that the concomitant presentation of these two disease entities in our patient highlights a potentially unique treatment with imatinib mesylate. To our knowledge, this is the second reported case of both entities in the same patient. |
format | Online Article Text |
id | pubmed-8489551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-84895512021-10-13 Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment Eubanks, Bianca N Tafti, Dawood A House, Sabrina Logemann, Nicholas Cureus Dermatology Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome that affects multiple organ systems. We present the case of a 47-year-old African American male with a two-year history of a slowly enlarging right lower back lesion. Upon workup, the 3 × 2 cm mass was biopsied confirming a diagnosis of DFSP. This was identified in concert with axillary freckling, café-au-lait spots, and pedunculated plaques evaluated with biopsy. The findings were consistent with neurofibromas, leading to a new diagnosis of NF1. The patient was definitively treated with wide local excision of the DFSP lesion without tumor recurrence over six years. DFSP has a favorable prognosis when treated with wide local excision and negative surgical margins. However, lesions may recur with inadequate margins. Although deferred in our patient, treatment with imatinib mesylate, a tyrosine kinase inhibitor, may be employed in the setting of advanced disease, metastasis, positive surgical margins, or irresectable locations. Imatinib has also been used to treat NF1. Hence, we posit that the concomitant presentation of these two disease entities in our patient highlights a potentially unique treatment with imatinib mesylate. To our knowledge, this is the second reported case of both entities in the same patient. Cureus 2021-09-03 /pmc/articles/PMC8489551/ /pubmed/34650853 http://dx.doi.org/10.7759/cureus.17675 Text en Copyright © 2021, Eubanks et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Eubanks, Bianca N Tafti, Dawood A House, Sabrina Logemann, Nicholas Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment |
title | Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment |
title_full | Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment |
title_fullStr | Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment |
title_full_unstemmed | Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment |
title_short | Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment |
title_sort | dermatofibrosarcoma protuberans presenting in a patient with neurofibromatosis type 1: potential implications on treatment |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489551/ https://www.ncbi.nlm.nih.gov/pubmed/34650853 http://dx.doi.org/10.7759/cureus.17675 |
work_keys_str_mv | AT eubanksbiancan dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment AT taftidawooda dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment AT housesabrina dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment AT logemannnicholas dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment |